Astrazeneca PLC (NYSE:AZN)‘s stock had its “buy” rating reiterated by analysts at Cantor Fitzgerald in a report issued on Thursday.

Other analysts have also recently issued reports about the stock. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Astrazeneca PLC in a research note on Monday, August 8th. Shore Capital reiterated a “hold” rating on shares of Astrazeneca PLC in a research note on Wednesday, July 27th. Deutsche Bank AG reiterated a “buy” rating on shares of Astrazeneca PLC in a research note on Monday, October 10th. Citigroup Inc. reiterated a “buy” rating on shares of Astrazeneca PLC in a research note on Monday, November 7th. Finally, TheStreet upgraded shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a research note on Friday, July 22nd. Three analysts have rated the stock with a sell rating, eight have given a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. Astrazeneca PLC has an average rating of “Hold” and a consensus target price of $37.61.

Analyst Recommendations for Astrazeneca PLC (NYSE:AZN)

Shares of Astrazeneca PLC (NYSE:AZN) opened at 27.98 on Thursday. The firm has a market capitalization of $70.79 billion, a price-to-earnings ratio of 31.98 and a beta of 0.83. The company’s 50-day moving average is $30.57 and its 200-day moving average is $30.84. Astrazeneca PLC has a 12-month low of $26.97 and a 12-month high of $35.04.

Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, November 10th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.58. The firm earned $5.70 billion during the quarter, compared to analysts’ expectations of $5.95 billion. Astrazeneca PLC had a net margin of 10.35% and a return on equity of 30.40%. The company’s revenue was down 2.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.03 earnings per share. On average, equities analysts forecast that Astrazeneca PLC will post $2.99 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the stock. Creative Planning increased its stake in shares of Astrazeneca PLC by 114.5% in the second quarter. Creative Planning now owns 28,228 shares of the company’s stock valued at $852,000 after buying an additional 15,069 shares in the last quarter. NEXT Financial Group Inc increased its position in shares of Astrazeneca PLC by 8.8% in the second quarter. NEXT Financial Group Inc now owns 6,305 shares of the company’s stock valued at $190,000 after buying an additional 509 shares during the period. New England Research & Management Inc. bought a new position in shares of Astrazeneca PLC during the second quarter valued at about $777,000. Integrated Investment Consultants LLC increased its position in shares of Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock valued at $144,000 after buying an additional 275 shares during the period. Finally, First Financial Bank N.A. Trust Division increased its position in shares of Astrazeneca PLC by 7.3% in the second quarter. First Financial Bank N.A. Trust Division now owns 7,787 shares of the company’s stock valued at $235,000 after buying an additional 530 shares during the period. Institutional investors own 11.35% of the company’s stock.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

5 Day Chart for NYSE:AZN

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.